The Pharmacogenetics of Major Depression: Past, Present, and Future

@article{Laje2007ThePO,
  title={The Pharmacogenetics of Major Depression: Past, Present, and Future},
  author={Gonzalo Laje and Francis J. McMahon},
  journal={Biological Psychiatry},
  year={2007},
  volume={62},
  pages={1205-1207}
}

Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.

Genetic variation in HTR2A that was previously associated with citalopram treatment outcome was also associated with thalamic 5-HTT binding, suggesting that a relationship exists between genetic variations in H TR2A and either 5-htT expression or central serotonergic transmission that influences the therapeutic response to 5- HTT inhibition in major depression.

The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case–control association study

It is shown that none of the seven COMT SNPs, including the rs4680, was significantly associated with MDD after permutation correction in single SNP analyses, which suggests that the polymorphic COMT gene that influences catecholaminergic neurotransmission may play a role in the individual response to antidepressants.

Genetic variables of the glutamatergic system associated with treatment-resistant depression: A review of the literature

A literature search was performed to identify studies on the genetics of the glutamatergic system in depression, focused on variables related to NMDARs and AMPARs, and highlights GRIN2B, which encodes the NR2B subunit of N MDAR, as a candidate gene in the pathogenesis of TRD.

Genetic variation in HTR 2 A influences serotonin transporter binding potential as measured using PET and [ 11 C ] DASB

While further work is needed to identify the actual functional genetic variants involved, these results suggest that a relationship exists between genetic variation in HTR2A and either 5- HTT expression or central serotonergic transmission that influences the therapeutic response to 5-HTT inhibition in major depression.

Pharmacogenetics of Antidepressant Drugs: An Update

The major findings related to the pharmacogenetics of genes involved in the pharmacokinetics and pharmacodynamics of antidepressant drugs are critically reviewed.

Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase

DBH gene as predictor of response in a cocaine vaccine clinical trial

References

SHOWING 1-10 OF 22 REFERENCES

Predictors of response to antidepressants general principles and clinical implications.

  • A. Nierenberg
  • Psychology, Medicine
    The Psychiatric clinics of North America
  • 2003

Pharmacogenetic studies of antidepressant response: how far from the clinic?

  • R. Perlis
  • Medicine, Psychology
    The Psychiatric clinics of North America
  • 2007

Translating Pharmacogenomics: Challenges on the Road to the Clinic

This article presents specific clinical examples of such challenges and discusses how obstacles to implementation of pharmacogenomic testing can be addressed and how the application in patient care remains very limited.

Epigenetic Marking and Neuronal Plasticity

Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study

The study, which includes projections of the burden through the year 2020, uses the disability-adjusted life year as a composite measure of years of life lost due to premature mortality and years lived with disability.

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

There is a compelling case for a key role of HTR2A in the mechanism of antidepressant action, as detected in patients treated with the antidepressant citalopram.

Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region

Transporter-facilitated uptake of serotonin (5-hydroxytryptamine or 5-HT) has been implicated in anxiety in humans and animal models and is the site of action of widely used uptake-inhibiting

Pharmacogenomics and antidepressant drugs

These studies mark the beginning of an emerging standard SNP profiling system that ultimately allows identifying the right drug for the right patient at the right time.